By PPN News Staff
The FDA granted a new indication for upadacitinib (Rinvoq, AbbVie) for the treatment of severe atopic dermatitis in adults and children aged 12 years and older whose disease did not respond to previous treatment and is not controlled with other medications.
The medication was shown to significantly improve skin clearance (EASI 75 [≥75% reduction from baseline in the Eczema Area and Severity Index] and vIGA-AD 0/1 [Validated Investigator Global Assessment for Atopic Dermatitis